OneMedNet Stock Price, News & Analysis

OneMedNet (Nasdaq:ONMD) announced on October 20, 2025 that mlHealth360 has signed a multi-year subscription to OneMedNet’s iRWD™ platform for regulatory-grade, de-identified imaging and clinical data.

The subscription gives mlHealth360 ongoing access to curated X-ray and CT datasets sourced from 1,750+ healthcare provider sites and 131 million+ clinical studies, supporting AI model development, validation, and deployment. OneMedNet said the deal advances its subscription-based strategy and helps scale annual recurring revenue by expanding its customer base of AI and analytics firms.

Palantir Technologies (NASDAQ: PLTR) signed a multi-year agreement to provide its Artificial Intelligence Platform to OneMedNet’s iRWD™ near real-time AI provider network. The integration will combine Palantir analytics with OneMedNet access to 5 billion administrative claims, 131 million clinical exams and > 1,750 provider sites, spanning oncology, cardiology, and rare diseases. The platform aims to enable faster data discovery (minutes vs days), custom cohort creation, conversational AI search, automated workflows, and large-scale de-identification to deliver regulatory-grade, anonymized clinical data to life sciences and medical device customers. OneMedNet positions the partnership to pursue scalable recurring revenue and accelerate clinical research and AI-driven healthcare solutions.

OneMedNet (Nasdaq:ONMD) has announced a strategic partnership with Medcase to enter the $1.5 billion healthcare data annotation market. The collaboration leverages Medcase's network of 15,000+ healthcare professionals for medical data annotation services, while utilizing OneMedNet's iRWD™ platform and provider network for regulatory-grade, de-identified Real-World Data.

The partnership comes at a strategic time as the market is projected to reach $2.8 billion by 2030. The recent disruption caused by Scale AI's $14.8B investment from Meta has created opportunities for specialized healthcare providers. This collaboration positions OneMedNet to deliver recurring revenue streams by serving healthcare AI developers, pharmaceutical companies, and medical technology leaders.

OneMedNet (Nasdaq:ONMD) has expanded its partnership with one of the world's top five medical device companies through multiple revenue-generating projects under an evergreen master services agreement. The collaboration includes four distinct purchase orders focused on delivering regulatory-grade multimodal Real-World Data (RWD) to accelerate medical imaging AI model development.

The company leverages its iRWD™ network spanning over 1,750 provider sites to deliver comprehensive datasets that include advanced medical imaging data and complete patient histories. OneMedNet has already begun fulfilling these recent orders, demonstrating its efficient execution capabilities in providing curated, de-identified, and fit-for-purpose datasets for AI development, clinical trial enhancement, and healthcare outcome improvement.

OneMedNet (Nasdaq:ONMD) has significantly expanded its Cardiovascular Real-World Data (RWD) network by adding 85 cardiovascular centers and data sources, contributing approximately 2.7 million annual cardiovascular studies. This expansion positions OneMedNet as one of the largest providers of cardiovascular RWD.

The enhanced network provides de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) to life sciences companies, AI developers, and medical device manufacturers. This data is particularly valuable given that cardiovascular diseases (CVDs) cause 19.8 million deaths globally and generate $320 billion in annual costs in the US alone.

OneMedNet (NASDAQ:ONMD) has established a strategic partnership with Circle Cardiovascular Imaging (Circle CVI) to implement a new subscription revenue model. Circle CVI will utilize OneMedNet's iRWD™ platform to access de-identified cardiovascular imaging data from over 1,750 provider sites, encompassing 131 million exams.

The partnership enables Circle CVI to leverage OneMedNet's extensive real-world data network for AI model development, cardiac diagnostics, and treatment planning. Data delivery is expected within 30 days, marking a shift from one-time transactions to a continuous subscription-based collaboration focused on advancing cardiovascular healthcare innovation.

OneMedNet (NASDAQ:ONMD), an AI-powered Real-World Data company, reported significant financial improvements in Q2 2025. The company achieved an 80% reduction in total liabilities, decreasing from $19.7M to $6.2M, with an additional $1.9M reduction in July 2025.

Key financial highlights include $3.0M net income in Q2 2025, $3.7M raised through private placements, and holdings of 15 BTC valued at $1.6M. Operationally, OneMedNet expanded its provider network to 1,750 sites with access to 136M clinical studies, while enhancing its iRWD™ platform with improved AI capabilities and adding over 5 billion administrative records and claims.

OneMedNet (NASDAQ:ONMD), a leader in AI-powered Real-World Data (RWD), has announced a 25% expansion of its iRWD™ network and platform. The company now encompasses 1,750+ healthcare system partner sites, providing access to 34 million patients, 136 million clinical exams, and 5 billion administrative records.

The expansion significantly enhances OneMedNet's capability to provide insights into rare diseases, underserved populations, and health economics. Operating in the $60 billion RWE industry, the company is positioned for accelerated revenue growth through increased data licensing and new enterprise partnerships.

OneMedNet (NASDAQ:ONMD) has selected Inka Health, a subsidiary of Onco-Innovations, to spearhead an AI-driven oncology data analytics project focused on developing external control arms (ECAs) for clinical trials. The initiative aims to leverage OneMedNet's iRWD Real-World Data platform to create more efficient alternatives to traditional clinical trials.

The project will utilize Inka Health's SynoGraph platform, combining machine learning with causal inference methods, to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This collaboration targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030, and aims to accelerate cancer therapy development while reducing costs.